



INVESTOR PRESENTATION

RICHARD RENDELL CEO

September 2021

Disclaimer

This document is being issued for the sole purpose of providing information. This document should not be distributed, published or reproduced, in whole or in part, nor should its contents be disclosed by recipients to any other persons other than that person's professional advisers.

This document is not and should not be construed as an offer to sell or solicitation of an offer to buy any securities. The statements of facts, opinions and estimates contained in this document have been obtained, compiled or arrived at from sources believed to be reliable and in good faith, but no representation or warranty expressed or implied is made as to their accuracy, completeness or correctness.

Any numbers, valuations, and schedules contained in this document are preliminary and are for discussion purposes only. The information contained in this document is published for the assistance of its recipients but is not to be relied upon as authoritative or taken in substitution for the exercise of judgement by any recipient and no liability is accepted whatsoever for any direct or consequential loss arising from the use of this document or its contents.

All statements of opinion and/or belief contained in the document and all views expressed and all projections, forecasts or statements relating to expectations regarding future events or the possible future performance represent the relevant party's own assessment and interpretation of information available to it as at the date of this document. No representation is made, or assurance given that such statements, views, projections or forecasts are correct or that the objectives will be achieved.

COMPREHENSIVE PRECISION HEALTHCARE

- Heart disease remains the biggest killer in the world
- Death rates are estimated to double in the next 20 years
- Cardiac arrhythmias are responsible for 30% of all Strokes
- COVID-19 has increased cardiac disease risks
- Biosignals Diagnostics is a precision healthcare company
- Uses biometric data from specially designed, easily worn devices
- Better predict, diagnose and treat cardiac diseases
- Precision health from sport/lifestyle through to clinical care



Ask, Offer, Use of Funds & Exit Strategy

Ask & Offer

Total raising	AUD \$1,035,000
Pre-money valuation	AUD \$4,895,000
Ordinary shares	9,000,000 shares @ \$0.115
Equity offered	15%

Exit Strategy

Trade Sale or IPO/Listing

Use of Funds

Purchase of Hand-held wireless ECG devices and OEM agreement	20%
Complete product development of Next Generation Device	40%
Artificial Intelligence Cardiac Platform (Phase 2)	40%

Exit Examples

BioTelemetry \$2.8B sale to Philips in 2020
Flatiron \$1.9B sale to Roche in 2018
LifeWatch \$280M sale to BioTelemetry in 2017
Geneva Healthcare \$65M (data integration)

Who is Biosignals Dx?



Richard Rendell

Managing Director & Founder

Richard has recently been covered in **Forbes magazine** where he explains his experience in modern precision medicine and that it's now possible to begin tailoring treatments for cancer, heart disease, stroke and other serious diseases by analysing what makes some patients respond better than others. Richard has worked with distinguished scientists and medical practitioners at the frontlines of healthcare. All agree, that the next major leap will be a comprehensive approach to Risk, Prevention, Diagnosis and Treatment. This requires easy-to-use rapid deployment medical devices, that can acquire key biometric data, coupled with an intelligent platform that can interpret the clinical implications of these diverse information sources. This ultimately means predicting and preventing these serious diseases and ensuring the right treatments are available to patients faster, with a higher degree of confidence that the treatments will work.


This potential impact on healthcare inspires and drives Richard's deep personal commitment to deliver his vision through Biosignals Dx. Richard draws on a unique set of skills and experience from 15 years of board and CEO roles with medical device and precision medicine companies. Prior to that a long executive career at Oracle Corporation with global responsibilities for products with \$100M+ revenues. He also founded the advisory board and was CIO at iSelect Limited which listed on the ASX in June 2013.

Richard has assembled a highly capable and committed team to deliver the high impact value of Biosignals Dx as covered on pages 40-43.



Why Biosignals Dx?

QUADRUPLE AIM FOR CARDIAC DISEASE & STROKE CARE



Our product suite

Available now

ECG | me



Available 2022

ECG3 | me




Available 2024

OMNI | me






Available now

Intelligent Diagnostics & Management Platform



The problems we solve

Unmet Need	Approach	User	Our Solution
Detection of COVID-19 or vaccine impacts on cardiovascular system	Baseline and tracking	Consumer	ECG me 
Early detection of cardiac disease	On-demand cardiac assessment	Consumer	
Evaluation of concussion in sport	Rapid assessment of HRV	Sports/ Fitness	
Prevention of death and stroke from intermittent arrhythmias	Three-lead high accuracy device sending all heartbeats to cloud	Clinical	ECG3 me 
Effective outcomes for patients based on gender and ethnicity	Precision Cardiology	Clinical	OMNI me 

Additional unmet needs in diagnosis and treatment of diseases using ECG analysis currently under investigation

ECG | me

HAND-HELD PORTABLE WIRELESS ECG MONITOR



- ✓ Medical device
- ✓ TGA approved
- ✓ Ready to ship now
- ✓ Size of a credit card
- ✓ Post dialysis
- ✓ Medicine reviews
- ✓ Pre-diabetes screening
- ✓ Performance training & tracking
- ✓ Personal trainers
- ✓ Concussion Assessments

ECG3 | me

FEATURES TO LEAD THE CURRENT MARKET




*Picture from device design specifications.
Estimated delivery from manufacturing in Jan 2022.*

- ✓ 3 Leads
- ✓ Stores all heartbeats on device
- ✓ Streams all heartbeats to the cloud
- ✓ Rechargeable
- ✓ Indefinite monitoring
- ✓ Heart Rate Variability
- ✓ Obstructive Sleep Apnea detection
- ✓ Sleep disordered breathing analysis
- ✓ Multiple cardiovascular diseases
- ✓ Mobile device shows ECG and results
- ✓ Patient comfort

OMNI | me

FUTURE DISRUPTIVE PRODUCT - planned Q4 2025




- ✓ Body Area Network (BAN)
- ✓ Graphene sensors roll-on like a tattoo
- ✓ Zero noise
- ✓ Detects more than ECG alone
- ✓ Streams data to cloud platform
- ✓ Detection and management of diseases
- ✓ Sporting and other applications
- ✓ Patient portal gives access to results
- ✓ Patient comfort

Multiple Patents and associated Intellectual Property expected and wholly owned by Biosignals Dx.

Biosignals Dx system

FAST ACCURATE ANALYSIS - EVERY BEAT IN REAL TIME



Cardiac Telemetry – Clinical Competitor Matrix

Company	Model	ECG stream to cloud	Phone App	No. of Channels	Patient Portal	Unlimited Arrythmia Profiles	Other Diseases Assessed	AI Machine Learning	Cardiology Workbench Platform	Analyses External Non-ECG Data	Stroke Risk Assessment	AI Chat Bot Diary	Monitoring Period	On-device Storage
BiosignalsDx	ECG3 me	✓	✓	3	✓	✓	✓	✓	✓	✓	✓	✓	Indefinite	7 Days
Bittum	Faros	✗	✓	3	✓	✓	✗	✗	✗	✗	✗	✗	30 Days	180 days
Medicomp	TelePatch	✗	✗	2	✗	✓	✗	✗	✗	✗	✗	✗	30 Days	Not Stated
Hemodynamics	EZecg Patch	✗	✗	1	✗	✓	✗	✗	✗	✗	✗	✗	7 Days	7-day ECG
LifeSignals	LP1100 LS	✗	✓	3	✓	✗	✗	✗	✗	✗	✗	✗	5 Days	Not Stated
Qardio	QardioCore	✗	✓	1	✓	✗	✗	✗	✗	✗	✗	✗	1 Day	Not Stated
VitalConnect	VitalPatch	✗	✓	1	✗	✗	✗	✗	✗	✗	✗	✗	7 Days	10-hour data
G Medical	GMP	✗	✗	1	✗	✗	✗	✗	✗	✗	✗	✗	14 Days	Not Stated
Biotel	ePatch	✗	✗	3	✗	✗	✗	✗	✗	✗	✗	✗	14 Days	2GB
Peerbridge	CorXT	✗	✓	2	✗	✗	✗	✓Beat analysis only	✗	✗	✗	✗	7 Days	Not Stated
iRhythm	zioXT	✗	✗	1	✗	✗	✗	✓Noise reduction & detect arrhythmia	✗	✗	✗	✗	14 Days	14 Days

Precision healthcare

BIOSIGNALS BRING GREATER PRECISION



RISK

Is the patient likely to develop this disease ?



PREVENTION

What actions can reduce likelihood of the disease?



DIAGNOSIS

Does the patient have the disease now?



TREATMENT


Which therapeutic pathways for this patient?

The precision medicine market is expected to reach USD 126.14 Billion at a 12.48% CAGR by 2025¹.

¹<https://www.medgadget.com/2021/02/precision-medicine-market-size-is-anticipated-to-reach-usd-126-billion-at-a-12-48-cagr-by-2025.html>

Cardiovascular Disease & Stroke

ATRIAL FIBRILLATION CAUSES STROKE



Women experience heart attack differently

- On average, 1 woman dies from a heart attack every 3 hours
- In 2019, 45% of all deaths from heart attack were women.
- Every 27 minutes, one Australian woman has a heart attack.

DIFFERENT SYMPTOMS

- pressure or pain in the lower chest or upper abdomen
- extreme or unexplained fatigue
- pain or discomfort in the back, neck, stomach, or jaw
- feeling light-headed or dizzy
- pain or discomfort in one or both arms
- cold sweats, nausea, or vomiting
- shortness of breath

Ethnicity



- Prediction accuracy is not consistent across ethnicities
- Different populations have significant genome differences
- Responses to drugs vary from no response to toxic
- Living in a different culture to the ethnic background
- Geographic location is often larger predictor

DIFFERENCES CAN RESULT IN DEATH

- Metabolization of treatment drugs too low or high
- Comorbidities can have greater or unseen impact
- Some more likely to die from stroke
- Recovery from cardiac event causes another event
- Assumptions made in emergency treatment

Comorbidities

- Having other diseases causes greater cardiovascular risk
- 2 out of 3 adults with Diabetes will die from a cardiovascular event
- COVID-19 causes long-term risk of cardiac complications
- Cancer (metastatic solid tumours) and treatments
- Cardiovascular disease #1 cause of death in Rheumatoid Arthritis

UNDISCOVERED SYMPTOMS

- Unknown disease status
- Many people unaware they are in a pre-diabetic phase
- Some more likely to die from stroke
- Recovery from cardiac event causes another event
- Assumptions made in emergency treatment



OMNI | me - precision health


Current methods for diagnosing and treating cardiovascular diseases are failing us because they do not account for the vast differences in Gender, Ethnicity, Genetics and Comorbidities for example. Precision Health is the recognised way forward for improving healthcare and preventing deadly cardiovascular diseases more effectively.

OMNI | me DEVICE

- ✓ Body Area Network
- ✓ Graphene roll-on tattoo sensors
- ✓ Measures many biometric signals incl. ECG


OMNI | me PLATFORM

- ✓ Risk, Prevention, Diagnosis, Treatment
- ✓ Precision cardiology then other diseases
- ✓ Supports new drugs and treatments




OMNI | me platform

HOW BIOSIGNALS DIAGNOSTICS ENABLES PRECISION HEALTH



- ✓ Platform including medical devices
- ✓ Total life context
- ✓ Caters for ethnicity and gender
- ✓ Biosignals Dx body area networks
- ✓ Unrivalled clinical trial platform
- ✓ Detection and management of diseases
- ✓ Sporting and clinical application
- ✓ Patient portal gives access to everything
- ✓ Telemedicine access to doctors

Disruptive clinical business model



DIRECT TO CLINICAL AND DIRECT TO CONSUMER

Market Models - Comparison

	Distributor Model	Biosignals Dx Service Model
Revenue Source	Biosignals Dx sells device through a Distributor	Biosignals Dx provides a <u>reimbursable</u> cardiac monitoring service directly to customers across several clinical markets incl. Cardiologists & GP's
Financial Impact	CAPEX	Small revenue share to the clinic
Revenue Profile	Once-off Sale (of device)	Recurring (fee for each patient monitor session)
Product/Service	Device and basic software	Biosignals Dx service fee includes; device, electrodes, report from cloud platform, cardiac technologist evaluation and a Cardiologist's diagnosis including sign-off.
Pricing Model	Device manufacturing cost + margin	Fee based on Service Type per patient (Achieves 4x Distributor Model Revenue)

Biosignals Dx also opens markets beyond Cardiologists and GP's using our disruptive service model.

Revenue Comparison - Distributor vs Service Models

Model	Device	Session Report	ECG Analysis	Cardiologist Assess & Sign-off	Device Sale Revenue	Report Revenue	Service Fee / Patient Session	*Per Device Revenue (3 years)
Distributor	Purchased	Yes	No	No	\$3,600	\$20	0	\$5,760
Service	Free	Yes	Yes	Yes	0	0	\$197	\$21,276


The Biosignals Dx Service Model is a **4x** revenue multiplier when compared to the Distributor Model by providing the ECG monitoring device free of charge and instead billing a service fee each time the device is used.

**Based on average 3 uses per month for 36 months in an Australian General Practice deployment.*

Services Progress

Service Line	Decision Makers	Progress
General Practitioners	General Practitioner	Sign up of initial 3 clinics Mar 2022.
Pharmacy Services	Pharmacy Company Executives & Chief Pharmacist	Australian Pharmacy chain. Contract sign-off expected Mar 2022.
Aged Care	Facility Management Attending GP's	Trial expected to commence June 2022.
Telemedicine	Telemedicine Platform Executives Rural hospital doctors and management	Discussion with rural hospitals and remote telemedicine providers indicate a strong alignment for the services model in remote settings. Trials expected March 2022.

Market Opportunity



Hand Held Wireless Device (Australia)

Service Line	Service Type	Pricing Ranges (device + 12mth)	Est. 3rd year revenue (AU\$)
Primary Care / Cardiology Clinic	Diagnostic	\$90-\$150	\$2.0M
Aged Care	Diagnostic/Screening	\$20-\$40	\$0.6M
Pharmacy Services	Screening	\$20-\$40	\$0.6M
^Direct to Consumer	Health/Sport/Fitness	\$300-\$400	\$8.5M
Total			\$11.7M*

** Detailed expenditure breakdown can be provided in the spreadsheet addendum. NOTE: All numbers are estimates only, no representation is made, or assurance given that such statements, views, projections or forecasts are correct or that the objectives will be achieved. See full Disclaimer on Slide 2.*

^ Device is purchased by consumer and 12 month subscription included \$10/mth.

Service Lines – 3 Lead Device (Australia)

Service Line	Service Type	Pricing Ranges (per session)	Est. 3rd year revenue (AU\$)
Primary Care / Cardiology Clinic	Diagnostic	\$150-\$300	\$1.1M
Aged Care	Diagnostic/Screening	\$100-\$200	\$0.5M
Pharmacy Services	Screening	\$80-\$150	\$1.2M
^Telemedicine	Diagnostic/Screening	\$80-\$200	\$0.9M
Total			\$3.7M*

** Detailed expenditure breakdown can be provided in the spreadsheet addendum. NOTE: All numbers are estimates only, no representation is made, or assurance given that such statements, views, projections or forecasts are correct or that the objectives will be achieved. See full Disclaimer on Slide 2.*

*^ Telemedicine is a **modality** of service delivery, enabling broader reach of existing diagnostics in remote rural settings*

Service Lines – 3 Lead Device (USA)

Service Line	Service Type	Pricing (per session)	Est. 3rd year revenue (AU\$)
Primary Care	Diagnostic	\$400-\$600	\$3.3M
Aged Care	Diagnostic/Screening	\$200-\$400	\$1.6M
Veterans Hospitals (DVA)	Diagnostic/Screening	\$300-\$500	\$5.2M
Pharmacy Services	Screening	\$80-\$150	\$1.4M
^Telemedicine	Diagnostic/Screening	\$100-\$300	\$3.6M
Total			\$15.1M*

* Detailed expenditure breakdown can be provided in the spreadsheet addendum. NOTE: All numbers are estimates only, no representation is made, or assurance given that such statements, views, projections or forecasts are correct or that the objectives will be achieved. See full Disclaimer on Slide 2.

^Telemedicine is a **modality** of service delivery, enabling broader reach of existing diagnostics in remote rural settings

Collaborations

Collaborator*	Type	Purpose	Status
GP Clinics (x2)	Private Clinic	Patient trials, service refinement and data	Preliminary discussions complete.
Cardiology Clinic	Private Clinic	Patient trials, service refinement and data	Preliminary discussions complete.
Tier 1 University (Australia)	Faculty of Computer Science	AI algorithm development and data sources, KOL's	Initial introductions via Uni's Head of Commercialization and selection of applicable resources underway.
Tier 1 University (Australia)	Faculty of Medicine (incl. teaching hospital)	Cardiac disease management, patient trials and data, KOL's	Initial introductions via Uni's Head of Commercialization and selection of applicable projects/resources underway.
Oracle Corporation	Multi-national Company	Computing and IT resources, AI tools	Preliminary discussions complete. Agreed pending formal signoff.

**Further details of collaborators and KOL's cannot be made public yet, however specific information can be provided under non-disclosure.*

Product & Commercialisation Roadmap


ECG | me



ECG3 | me



OMNI | me



Consumer Revenue

Clinical Revenue

Disease Management Revenue

Est. First Revenues
Q4 CY21

Est. First Revenues
Q4 CY22

Est. First Revenues
Q3 CY23

People



Christopher Pendlebury
Chief Science Officer

Christopher is a commercial data scientist with a background in medical biotechnology and mathematics. With over ten years of experience at the nexus between new and emerging technologies in molecular biology, bioinformatics, big data and new models of genomic analysis for clinical use through AI and Machine Learning. Chris implemented the unique codon-context DNA algorithm for GMDx Genomics which is now capable of predicting responders/non-responders to immunotherapy drugs and predicting Cancer progression with up to 99% accuracy.

Prior to GMDx, Chris worked on a range of genomics and bioinformatics projects in conjunction with Applied Precision Medicine Pty Ltd and Appistry LLC in the US. These projects included collaboration with key US genomic scientists from Washington University (St. Louis) who had contributed to the original mapping of the human genome. Chris worked locally supporting Appistry's genomic analysis appliances and software pipelines in Australia with GeneWorks, QIMR, Monash University, University of Melbourne, University of Western Australia and the Australian Department of Primary Industries. Through a collaboration with GeneWorks, Chris consulted to Pfizer on bioinformatics relating to gene expression and his work enabled a new drug approach which was ultimately patented by Pfizer.

Recently Chris has enabled early work on ECG pre-processing and genetics associated with arrhythmias. He holds a Bachelor of Biotechnology with Honors from Monash University.



Hayden Pitout
Chief Technology Officer

An internationally experienced CTO and software engineer who has successfully delivered diagnostic products, platforms and services in Health Technology and Pharmacogenomics, with a focus on the personalised treatment of severe mood disorders and the impact of polypharmacy within major drug classes including: Psychiatry, Pain, Cardiology, Diabetes, Gastroenterology, Endocrinology and Alzheimer's. Hayden has delivered multiple genetic-test products RxMatch™, Amplis™ and AmplisEvo™ into the US markets, working with healthcare providers including; Intermountain Healthcare, Coriell Life Sciences and Ramsay Healthcare in Australia where he was responsible for the the end-to-end delivery of the AmplisEvo™ Clinical Trial through Ramsay Health Care Australia in 2020.



Kevin Hollingsworth
Company Secretary, CFO

Kevin Hollingsworth is a Fellow of CPA Australia, a Fellow of Chartered Management Accountants and a Chartered Global Management Accountant. He is currently CFO and Company Secretary of Paradigm Biopharmaceuticals Ltd (ASX: PAR). Prior to that CFO and Company Secretary of Mesoblast (ASX:MSB) and several other ASX listed companies. Previous professional roles as National President of CIMA Australia and a State Councilor for CPA Australia.

People



Lexie Qin
Head of Product Engineering

Lexie is an experienced Biomedical Engineer, covering the end-to-end process of developing a medical device, including Intellectual Property strategy, regulatory strategy and commercialisation strategy. Lexie contributed to initial requirements, established development and manufacturing for the Biosignals Dx Next Generation device in China. She is a key contributor to the design and development of the future flagship product (the advanced multi-function monitor). Lexie has a Bachelor of Biomedical Engineering, from Beijing University of Technology and a Master of Biomedical Engineering from Melbourne University. Lexie is also a certified English – Chinese translator.



Renee Ge
AI and Data Sciences Engineer

Renee is a competent young professional bringing 2 years of practical experience, in acquiring, interpreting and analysing data in a fast-paced environment to deliver complex data analysis outcomes including predictive models. Renee has extensive skills in AI languages such as Python and R with deep understanding of the application of machine learning the clinical healthcare context. Renee is currently working on a major project at Monash University "Monitoring health and wellbeing of seniors using unobstructive sensors" where she has developed computational models for the automatic continuous assessment of functional decline and onset of medical conditions. Renee is a certified English – Chinese translator.

Advisory

**Stephan G. Foy**

*MB ChB MD (Otago) FRACP FCSANZ
Consulting Cardiologist & Clinical Advisor*

A graduate of University of Otago, Stephan gained his post-graduate Doctor of Medicine by research work at The Princess Margaret Hospital, Christchurch, NZ. After completing his Interventional Fellowship (Percutaneous Coronary Interventions) at Royal Perth Hospital, WA, Stephan was appointed as Consultant Cardiologist at Launceston General Hospital, Tasmania. Stephan's expertise in invasive cardiac techniques led him to establish the invasive cardiac services at Launceston General Hospital. He implemented the hospital's cardiac catheterisation and permanent pacemaker implantation services. Stephan had a leading role in the development and implementation of the Cardiac Services at St John of God Hospital, Geelong. He has been a key advisor to the hospital's Cardiac Catheterisation and Interventional Cardiology programmes and Cardiac Care Unit. Stephan's professional affiliations include Fellow Royal Australasian College of Physicians and Fellow Cardiac Society of Australia and New Zealand.

**Advisor (TBC)**

Artificial Intelligence (Healthcare)

Highly qualified person has been identified with extensive experience in Artificial Intelligence and machine learning in clinical decision support. Advisory role to be offered subject to funding.

**Advisor (TBC)**

Genomics

Highly qualified person has been identified with extensive experience in clinical genomics. Advisory role to be offered subject to funding.

**Advisor (TBC)**

US Healthcare & Reimbursements

Highly qualified person has been identified with extensive experience in US Healthcare and Reimbursements. Advisory role to be offered subject to funding.

**Advisor (TBC)**

Stroke and Neurological Sciences

Highly qualified person has been identified with extensive experience in Stroke and Neurological Sciences. Advisory role to be offered subject to funding.

Investment summary

- ✓ Total raising **AUD \$1,035.00**
- ✓ Pre-money valuation **AUD \$4,895,000**
- ✓ Equity offered **15%**
- ✓ Target markets are clinical and consumer (one device)
- ✓ Hand-held device has TGA approval
- ✓ Sporting, Pharmacy, Aged Care applications
- ✓ Generating revenue by Nov 2021
- ✓ Demand from clinical and consumer groups confirmed
- ✓ 3 Lead device development to complete Dec 2021
- ✓ Reimbursements up to US \$600 per session clinical use
- ✓ First of 6 patents to be filed Jan 2022

RICHARD RENDELL CEO

E: richard@biosigdx.com

T: +61 3 9629 9899

Biosignals Diagnostics Pty Ltd
Suite 201, 517 Flinders La
Melbourne Victoria 3000
Australia
ACN 642 479 874